bioage initial public offering news

Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.

pharmaphorum · 1d

Obesity drug developer BioAge raises $198m in IPO

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.

BioPharma Dive · 1d

BioAge prices $198M IPO, validating pivot to obesity drug research

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.

BioAge seeks nearly $200 million in initial public offering

BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...

BioAge Labs Announces Pricing of Upsized Initial Public Offering

BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of ...

1don MSN

BioAge, BKV shares end their first trading day flat after earlier gains

Obesity-drug developer BioAge jumps nearly 30% while Texas-based Barnett Shale driller BKV posts smaller gain.

Biopharma News | Today's Latest Stories | Reuters

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

10h

RTW Biotech notes BioAge Labs' USD198 million initial public offering

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million initial public offering.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results